Gabriele Varano

Dr. Gabriele Varano

Department of Translational Medicine, University of Ferrara

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MCMarieta Caganova
Marieta Caganova
CCChiara Carrisi
Chiara Carrisi
GVGabriele Varano
Gabriele Varano
FMFederica Mainoldi
Federica Mainoldi
FZFederica Zanardi
Federica Zanardi
SCStefano Casola
Stefano Casola
Protection against deadly pathogens requires the production of high-affinity antibodies by B cells, which are generated in germinal centers (GCs). Alteration of the GC developmental program is common in many B cell malignancies. Identification of regulators of the GC response is crucial to develop targeted therapies for GC B cell dysfunctions, including lymphomas. The histone H3 lysine 27 methyltransferase enhancer of zeste homolog 2 (EZH2) is highly expressed in GC B cells and is often constitutively activated in GC-derived non-Hodgkin lymphomas (NHLs). The function of EZH2 in GC B cells remains largely unknown. Herein, we show that Ezh2 inactivation in mouse GC B cells caused profound impairment of GC responses, memory B cell formation, and humoral immunity. EZH2 protected GC B cells against activation-induced cytidine deaminase (AID) mutagenesis, facilitated cell cycle progression, and silenced plasma cell determinant and tumor suppressor B-lymphocyte–induced maturation protein 1 (BLIMP1). EZH2 inhibition in NHL cells induced BLIMP1, which impaired tumor growth. In conclusion, EZH2 sustains AID function and prevents terminal differentiation of GC B cells, which allows antibody diversification and affinity maturation. Dysregulation of the GC reaction by constitutively active EZH2 facilitates lymphomagenesis and identifies EZH2 as a possible therapeutic target in NHL and other GC-derived B cell diseases.

28 December 2009 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MJMichelle L. Janas
Michelle L. Janas
GVGabriele Varano
Gabriele Varano
KGKristjan Gudmundsson
Kristjan Gudmundsson
MNMamiko Noda
Mamiko Noda
TNTakashi Nagasawa
Takashi Nagasawa
MTMartin Turner
Martin Turner
T cell development requires phosphatidylinositol 3-kinase (PI3K) signaling with contributions from both the class IA, p110δ, and class IB, p110γ catalytic subunits. However, the receptors on immature T cells by which each of these PI3Ks are activated have not been identified, nor has the mechanism behind their functional redundancy in the thymus. Here, we show that PI3K signaling from the preTCR requires p110δ, but not p110γ. Mice deficient for the class IB regulatory subunit p101 demonstrated the requirement for p101 in T cell development, implicating G protein–coupled receptor signaling in β-selection. We found evidence of a role for CXCR4 using small molecule antagonists in an in vitro model of β-selection and demonstrated a requirement for CXCR4 during thymic development in CXCR4-deficient embryos. Finally, we demonstrate that CXCL12, the ligand for CXCR4, allows for Notch-dependent differentiation of DN3 thymocytes in the absence of supporting stromal cells. These findings establish a role for CXCR4-mediated PI3K signaling that, together with signals from Notch and the preTCR, contributes to continued T cell development beyond β-selection.

10 November 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMarija Mihailovich
Marija Mihailovich
MBMichael Bremang
Michael Bremang
VSValeria Spadotto
Valeria Spadotto
DMDaniele Musiani
Daniele Musiani
EVElena Vitale
Elena Vitale
Tiziana BonaldiTiziana Bonaldi
Tiziana Bonaldi
The synergism between c-MYC and miR-17-19b, a truncated version of the miR-17-92 cluster, is well-documented during tumor initiation. However, little is known about miR-17-19b function in established cancers. Here we investigate the role of miR-17-19b in c-MYC-driven lymphomas by integrating SILAC-based quantitative proteomics, transcriptomics and 3′ untranslated region (UTR) analysis upon miR-17-19b overexpression. We identify over one hundred miR-17-19b targets, of which 40% are co-regulated by c-MYC. Downregulation of a new miR-17/20 target, checkpoint kinase 2 (Chek2), increases the recruitment of HuR to c-MYC transcripts, resulting in the inhibition of c-MYC translation and thus interfering with in vivo tumor growth. Hence, in established lymphomas, miR-17-19b fine-tunes c-MYC activity through a tight control of its function and expression, ultimately ensuring cancer cell homeostasis. Our data highlight the plasticity of miRNA function, reflecting changes in the mRNA landscape and 3′ UTR shortening at different stages of tumorigenesis.

1 November 2021 in Environmental Pollution
Verified
Journal Article
Closed access
ICIlaria Conti
Ilaria Conti
CSCarolina Simioni
Carolina Simioni
GVGabriele Varano
Gabriele Varano
CBCinzia Brenna
Cinzia Brenna
ECEva Costanzi
Eva Costanzi
LNLuca Neri
Luca Neri

31 May 2017 in Nature
Verified
Journal Article
Closed access
PDF file
GVGabriele Varano
Gabriele Varano
SRSimon Raffel
Simon Raffel
MSMartina Sormani
Martina Sormani
FZFederica Zanardi
Federica Zanardi
SLSilvia Lonardi
Silvia Lonardi
SCStefano Casola
Stefano Casola

15 January 2020 in Cells
Verified
Journal Article
Open access
PDF file
ICIlaria Conti
Ilaria Conti
GVGabriele Varano
Gabriele Varano
CSCarolina Simioni
Carolina Simioni
ILIlaria Laface
Ilaria Laface
DMDaniela Milani
Daniela Milani
LNLuca Neri
Luca Neri
MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression at the posttranscriptional level, inducing the degradation of the target mRNA or translational repression. MiRNAs are involved in the control of a multiplicity of biological processes, and their absence or altered expression has been associated with a variety of human diseases, including cancer. Recently, extracellular miRNAs (ECmiRNAs) have been described as mediators of intercellular communication in multiple contexts, including tumor microenvironment. Cancer cells cooperate with stromal cells and elements of the extracellular matrix (ECM) to establish a comfortable niche to grow, to evade the immune system, and to expand. Within the tumor microenvironment, cells release ECmiRNAs and other factors in order to influence and hijack the physiological processes of surrounding cells, fostering tumor progression. Here, we discuss the role of miRNAs in the pathogenesis of multicomplex diseases, such as Alzheimer’s disease, obesity, and cancer, focusing on the contribution of both intracellular miRNAs, and of released ECmiRNAs in the establishment and development of cancer niche. We also review growing evidence suggesting the use of miRNAs as novel targets or potential tools for therapeutic applications.